Medicamen Organics Limited (NSE: **MEDICAMEN**) is an established Indian pharmaceutical company specializing in the development, manufacturing, and distribution of a broad range of generic dosage forms. Following its successful listing on the **NSE Emerge** in **June 2024**, the company is undergoing a strategic transformation from a traditional B2B contract manufacturer to a brand-led global healthcare and personal care player. --- ### **Manufacturing Infrastructure & Production Capabilities** The company operates two **WHO-GMP** and **ISO 9001:2015** certified facilities in Haridwar, Uttarakhand, spanning **21,536 sq. ft.** These units are the backbone of its pharmaceutical operations. | Facility | Focus Area | Key Products | | :--- | :--- | :--- | | **Unit-1** | Specialized Production | Exclusive production of **Iron Tablets** (Ferrous Sulphate) | | **Unit-2** | General Formulations | Non-Beta lactam Tablets, Capsules, Oral Liquids, Ointments | **Annual Installed Capacities (FY 2023-24):** * **Tablets (Unit 1 & 2):** **21,600 Lakh units** * **Capsules:** **780 Lakh units** * **Suspension/Oral Liquids:** **936,000 Litres** * **Ointments/Creams:** **93,600 Kg** * **Dry Powder Sachets:** **3,744,000 Units** **Operational Status:** The facilities currently operate at **60% to 65%** utilization. A **20% capacity expansion** (adding approx. **21.6 crore tablets**) is underway as of mid-2025 to meet rising export demand. The Haridwar site has a peak manufacturing turnover potential of **₹100 Crores**. --- ### **Core Pharmaceutical & Specialized Product Portfolio** The company manages a diverse portfolio of **84 registered products** across multiple therapeutic areas, ranging from essential generics to critical care. * **Core Generics:** Includes **Anti-Bacterial, Anti-Diabetic, Anti-Hypertensive, and Anti-Viral** categories. Key products include **Rabeprazole & Domperidone** (Hyperacidity), **Tacrolimus** (Immunosuppressant), and **Ribavirin** (Hepatitis C). * **Nutraceuticals:** Licensed since **2010**, this segment produces protein powders, immunity boosters, and herbal health products. * **Topicals & Liquids:** A wide range of antifungal/antibacterial creams (e.g., **Miconazole, Nystatin, Mometasone**) and oral suspensions for cough, acidity, and deworming. * **Specialty Care:** Emerging focus on **Oncology**, Nephrology (Dialysis support), and **Vaccines/Biologics** for infectious diseases. --- ### **Strategic Pivot: The LOIRE Brand & Personal Care Vertical** In **Q1 FY 2025-26**, the company launched its premium personal care vertical under the brand **LOIRE**, managed by its subsidiary **Grande Etoile Pharmaceuticals Limited (GEPL)**. * **Product Scope:** Skincare (serums, moisturizers), Haircare (anti-dandruff), and female intimate hygiene. All products are **cruelty-free, paraben-free, and sulfate-free**. * **Investment & Targets:** An initial investment of **₹3 Crores** has been deployed for an omnichannel rollout. * **Revenue Goals:** Management targets **₹10 Crore** in sales from Nepal in Year 1, with a total vertical revenue target of **₹15 Crores** for FY 2026. The long-term goal is a **50% CAGR** over five years for this segment. --- ### **Global Expansion & Subsidiary Ecosystem** Approximately **70% of sales** are driven by international markets. The company is aggressively shifting from merchant-led exports to a **direct-to-market model** through strategic subsidiaries. * **Rwanda (Depot Pharmacy Yego Ltd - 51% stake):** Serves as the East African distribution hub. Target: **100 product registrations** by Dec 2025 and **USD 1.5 million** in sales for FY 2025-26. * **Francophone West Africa (GEPL - 50.92% stake):** Targeting Senegal, Mali, and Ivory Coast with a goal of **120 registrations** within two years. * **Nepal Manufacturing Hub (Medi Hub Organic Ltd - 30% stake):** MOL is investing **₹9 Crores** in this **EU-approved** facility. It is projected to have a revenue potential exceeding **₹400 Crores** and will facilitate entry into regulated European markets by late 2026. * **Direct Presence:** Operations commenced in **Mauritius** (July 2025); entry into **Brazil, Tanzania, and the Middle East** is targeted by March 2026. --- ### **Financial Performance & Capital Structure** Medicamen has shown robust growth, particularly in export revenue and operational efficiency. **Audited Financial Highlights (₹ in Lakhs):** | Metric | FY 2024 | FY 2023 | FY 2022 | | :--- | :---: | :---: | :---: | | **Revenue from Operations** | **2,527.17** | **2,214.71** | **2,097.52** | | **EBITDA** | **476.00** | **268.00** | - | | **Profit After Tax (PAT)** | **263.43** | **125.27** | - | | **Export Growth (%)** | **279.86%** | - | - | **H1 FY25 Performance:** * **Total Revenue:** **₹16.86 Crore** (up **48.91%** YoY). * **PAT:** **₹1.51 Crore** (up **10.88%** YoY). * **Target Margins:** Management is targeting a **10% PAT margin** and a **24% EBITDA margin**. **Capital Management:** * **IPO (June 2024):** Raised **₹10.54 Crore** at **₹34/share**. * **Warrants & Preferential Issues:** In early 2025/2026, the company issued warrants and converted **₹2.50 Crore** of unsecured loans into equity to strengthen the balance sheet and fund working capital. * **Debt Status:** The company currently maintains a **zero-debt** status. --- ### **Business Model & Market Dynamics** * **Revenue Mix Target:** **70% Pharmaceuticals** and **30% Personal Care**; **75% Exports** and **25% Domestic**. * **B2B Partnerships:** Supplies to **38 domestic companies** (including **Morepen, Wipro, Emami**) and **12 merchant exporters**. * **Government Tenders:** Supplies to **11 institutions**, including the armed forces and state hospitals. * **Seasonality:** Revenue is heavily weighted toward **Q4 (Jan–March)** due to government budget cycles. * **Working Capital:** High debtor days (**6-8 months**) are common in West African trade; the company is transitioning to **Letter of Credit (LC)** terms and direct exports to improve cash flow. --- ### **Risk Profile & Mitigation** * **Regulatory & Legal:** The company faces **4 civil recovery suits** and outstanding **Income Tax/GST demands** under appeal. Revenue is highly sensitive to the timing of international product registrations. * **Market Risks:** Exposure to **currency fluctuations** and **raw material volatility**. Mitigation includes moving toward **own-brand manufacturing** to gain better pricing power. * **Concentration Risk:** Historically dependent on a few large buyers; currently diversifying through the **LOIRE** brand and new geographic subsidiaries. * **Quality Compliance:** To mitigate competition, the company is upgrading plants to **EU quality standards** to move away from low-margin unorganized sectors.